China · Delayed Price · Currency is CNY Winner Medical Statistics
Total Valuation
Winner Medical has a market cap or net worth of CNY 16.37 billion. The enterprise value is 14.36 billion.
| Market Cap | 16.37B |
| Enterprise Value | 14.36B |
Important Dates
The last earnings date was Tuesday, August 25, 2026.
| Earnings Date | Aug 25, 2026 |
| Ex-Dividend Date | Sep 2, 2026 |
Share Statistics
Winner Medical has 574.92 million shares outstanding. The number of shares has decreased by -0.23% in one year.
| Current Share Class | 574.92M |
| Shares Outstanding | 574.92M |
| Shares Change (YoY) | -0.23% |
| Shares Change (QoQ) | -0.93% |
| Owned by Insiders (%) | 71.34% |
| Owned by Institutions (%) | 8.59% |
| Float | 159.03M |
Valuation Ratios
The trailing PE ratio is 20.98 and the forward PE ratio is 17.37.
| PE Ratio | 20.98 |
| Forward PE | 17.37 |
| PS Ratio | 1.47 |
| PB Ratio | 1.31 |
| P/TBV Ratio | 1.70 |
| P/FCF Ratio | 17.38 |
| P/OCF Ratio | 9.99 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.62, with an EV/FCF ratio of 15.24.
| EV / Earnings | 18.19 |
| EV / Sales | 1.29 |
| EV / EBITDA | 7.62 |
| EV / EBIT | 11.73 |
| EV / FCF | 15.24 |
Financial Position
The company has a current ratio of 1.88, with a Debt / Equity ratio of 0.24.
| Current Ratio | 1.88 |
| Quick Ratio | 1.39 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | 1.58 |
| Debt / FCF | 3.16 |
| Interest Coverage | 25.51 |
Financial Efficiency
Return on equity (ROE) is 6.79% and return on invested capital (ROIC) is 9.33%.
| Return on Equity (ROE) | 6.79% |
| Return on Assets (ROA) | 4.14% |
| Return on Invested Capital (ROIC) | 9.33% |
| Return on Capital Employed (ROCE) | 8.85% |
| Weighted Average Cost of Capital (WACC) | 3.70% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 15,855 |
| Asset Turnover | 0.60 |
| Inventory Turnover | 2.89 |
Taxes
In the past 12 months, Winner Medical has paid 223.36 million in taxes.
| Income Tax | 223.36M |
| Effective Tax Rate | 20.98% |
Stock Price Statistics
The stock price has decreased by -27.37% in the last 52 weeks. The beta is -0.02, so Winner Medical's price volatility has been lower than the market average.
| Beta (5Y) | -0.02 |
| 52-Week Price Change | -27.37% |
| 50-Day Moving Average | 29.39 |
| 200-Day Moving Average | 32.79 |
| Relative Strength Index (RSI) | 42.03 |
| Average Volume (20 Days) | 2,990,016 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Winner Medical had revenue of CNY 11.14 billion and earned 789.47 million in profits. Earnings per share was 1.36.
| Revenue | 11.14B |
| Gross Profit | 5.26B |
| Operating Income | 1.22B |
| Pretax Income | 1.06B |
| Net Income | 789.47M |
| EBITDA | 1.66B |
| EBIT | 1.22B |
| Earnings Per Share (EPS) | 1.36 |
Balance Sheet
The company has 5.80 billion in cash and 2.98 billion in debt, with a net cash position of 2.82 billion or 4.90 per share.
| Cash & Cash Equivalents | 5.80B |
| Total Debt | 2.98B |
| Net Cash | 2.82B |
| Net Cash Per Share | 4.90 |
| Equity (Book Value) | 12.49B |
| Book Value Per Share | 20.32 |
| Working Capital | 4.54B |
Cash Flow
In the last 12 months, operating cash flow was 1.64 billion and capital expenditures -696.87 million, giving a free cash flow of 942.31 million.
| Operating Cash Flow | 1.64B |
| Capital Expenditures | -696.87M |
| Depreciation & Amortization | 435.20M |
| Net Borrowing | 325.58M |
| Free Cash Flow | 942.31M |
| FCF Per Share | 1.64 |
Margins
Gross margin is 47.24%, with operating and profit margins of 10.99% and 7.09%.
| Gross Margin | 47.24% |
| Operating Margin | 10.99% |
| Pretax Margin | 9.56% |
| Profit Margin | 7.09% |
| EBITDA Margin | 14.90% |
| EBIT Margin | 10.99% |
| FCF Margin | 8.46% |
Dividends & Yields
This stock pays an annual dividend of 0.75, which amounts to a dividend yield of 2.53%.
| Dividend Per Share | 0.75 |
| Dividend Yield | 2.53% |
| Dividend Growth (YoY) | 14.29% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 56.34% |
| Buyback Yield | 0.23% |
| Shareholder Yield | 2.77% |
| Earnings Yield | 4.82% |
| FCF Yield | 5.75% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Winner Medical is 37.56, which is 31.88% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 37.56 |
| Price Target Difference | 31.88% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 9.08% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
The last stock split was on June 2, 2023. It was a forward split with a ratio of 1.4.
| Last Split Date | Jun 2, 2023 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
Winner Medical has an Altman Z-Score of 3.64 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.64 |
| Piotroski F-Score | 7 |